Source: PR Newswire

Press Release: Jazz Pharmaceuticals, Inc : Jazz Pharmaceuticals to Present Data at 2022 ASH Meeting Showcasing Commitment to Advancing Oncology Research

Key data includes results for intravenous administration of Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Patients DUBLIN, Nov. 3, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that...

Read full article »
Est. Annual Revenue
<$1M
Agree?
Est. Employees
<10
Agree?
CEO Avatar

CEO

Update CEO

CEO Approval Rating

- -/100